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Ebola virus is highly cytopathic through mechanisms that are largely unknown. We present evidence that progressive acidification of the
extracellular milieu by Ebola virus-infected cells combined with reduced levels of natural cysteine protease inhibitor makes the cells vulnerable to
uncontrolled proteolysis of extracellular matrix components by released active endosomal cathepsins, thereby exacerbating Ebola virus-induced
cell destruction. The cell surface microenvironment was shown to be crucial in aiding this activity. Blocking the proteolytic activity with the
cathepsin inhibitor E64 resulted in remarkable improvements with respect to viral cytopathicity and cell survival despite an overwhelmingly high
viral load. We propose that the observed enzymatic matrix degradation, enhanced by an associated protease/inhibitor imbalance and metabolic
acidosis, represents an effective viral strategy to boost infection and underlies, in part, the remarkable pathogenesis caused by Ebola virus. Further
in vitro and in vivo research will establish whether a cellular protease with hemorrhagic activity is the leading cause of vascular leakage–the
hallmark of Ebola virus hemorrhagic fever–and help understand the Ebola virus caused cell death.
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Ebola virus (EboV) is the causative agent of sporadic
outbreaks of severe hemorrhagic fever in human and non-
human primates in central Africa, associated with high-
mortality and rapidly progressive multiorgan failure. EboV is
highly cytopathic, and experimental evidence from a number of
laboratories has implicated the EboV glycoprotein GP in cell
cytotoxicity and injury (Rao et al., 1999; Takada et al., 2000;
Yang et al., 2000; Volchkov et al., 2001; Sullivan et al., 2005);
however, the details underlying EboV cytopathicity are still
largely unknown.
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doi:10.1016/j.virol.2006.08.018exotic viral disease. Herein, we report the finding of fully
processed and active cathepsin in the acidic extracellular milieu
of EboV-infected cells. Cathepsins are powerful enzymes that
belong to the cysteine proteases (CP) family and are found in all
cells and tissues (Rawlings et al., 2004) including the broad
range of cell lines susceptible to EboV infection. The main
physiological role of these enzymes is the metabolic degrada-
tion of intracellular proteins, and this activity is regulated by a
delicate balance between the enzyme and natural inhibitors. CPs
are synthesized as inactive pro-enzymes, and activation of the
enzyme is usually achieved by acidic pH and/or reducing
agents. Under certain circumstances, however, the enzyme can
move to the cell membrane and be secreted, a pathological
process that contributes to the development of many serious
human diseases. Given the large number of reports that
implicate secreted cathepsins in extracellular matrix degrada-
tion and disease progression (Nomura and Katunuma, 2005,
selected review), it seemed reasonable to speculate that
secretion of mature cathepsin by EboV-infected cells is a host
response that contributes to the severe nature of disease
Fig. 1. EboV-infected Vero E6 cells release fully processed, active CatL[B] into
the acidic extracellular milieu. (A) Immunodetection of pro- and mature CatL[B]
in TCF. Vero E6 cells were seeded and infected with EboVZ and EboVZe− at
∼0.1MOI. CP inhibitor E64 was either included (+I) or not included (−I) in the
maintenance medium. Mock infections were run in parallel. Supernatants were
harvested at the indicated days post-infection (d.p.i.) and treated with a cocktail
of protease inhibitors before Western blot analysis. The 45-kDa pro-enzyme
(Pro) and the 32-kDa mature (Mat) form of CatL[B] are indicated. (B) pH
profiles of infected TCF. pH values of the culture media were measured before
the supernatants from (A) were harvested. A non-glass pH meter with a fast-
response silicon chip pH sensor was used (IQ125 miniLab), and two-point
calibration was performed before each measuring session. The data from two
replicates were identical within the experimental error of the measurements;
error bars represent the instrumental error (±0.1pH).
2 Rapid Communicationprogression caused by this highly lethal pathogen. In the present
study, we investigated this possibility in Vero E6 cells infected
with the Zaire strain of EboV (EboVZ) and with a more
cytotoxic strain of the virus (EboVZe−) (Volchkov et al., 2001).
Vero E6 were infected at a multiplicity of infection (MOI) of 0.1
(or higher, only as indicated), leveling order to maximize the
difference in strain-dependent cytopathogenicity in these cells.
This current report is the second account that highlights
cathepsin proteases in connection with EboV infection. At the
time this work was conceived, a study using relatively high
concentrations (300 μM) of membrane-permeable cathepsin
inhibitor E64d demonstrated that endosomal cathepsin activity
is necessary for viral entry (Chandran et al., 2005). Our current
report adds further evidence to the notion that cathepsins act as
multifaceted host factors in EboV pathogenesis.
Results and discussion
A relatively straightforward proteomic analysis of glycopro-
teins extracted from tissue culture fluid (TCF) from EboVZ-
infected Vero E6 cells (described in the Supplementary text)
identified the host glycoprotein known in the literature as SPase
(Nishinaka et al., 1997; Fu et al., 1998; Nishinaka et al., 2005).
The name SPase is derived from the activity of this 32-kDa,
fully processed and active enzyme to selectively degrade
nuclear proteins, such as the transcription factor SP-1. To unify
the nomenclature, we renamed SPase as cathepsin-L[B],
hereafter referred to as CatL[B]. The identity of this protein
was further confirmed by recognition with a monoclonal
antibody (mAb) against CatL (Nishinaka et al., 1997) (Fig.
S1), and the specific patterns of activity were verified by use of
fluorometric assays (Table S1). CatL[B] is the monkey
orthologue of human cathepsin-L (CatL) that contains a unique
catalytic site with substrate specificity of cathepsin-B (CatB)
(Nishinaka et al., 1997). It exhibits enzymatic activity towards
Z-Arg-Arg-AMC, a synthetic substrate commonly used to
distinguish between human CatL and CatB (CatL usually does
not recognize this substrate). CatL[B]'s activity is completely
abolished in the presence of the broad-spectrum inhibitor E64
and the CatL/CatB inhibitor Z-FY(t-Bu)-DMK. In addition, we
found that the CatB-specific inhibitor CA074 significantly
attenuated this enzymatic reaction (Table S1).
To investigate whether extracellular CatL[B] plays any role in
the pathogenesis of EboV infection in vitro, we first examined the
relationship between the different biosynthetic forms of CatL[B]
detected in the purified material (Fig. S1). This was done in a
time-course experiment by Western blot analysis of TCF from
mock- and EboV-infected Vero E6 cells. A cocktail of protease
inhibitors in high-pH (8.0) buffer was added to the harvested
samples to exclude the possibility of artificial processing of the
protease precursor due to the use of detergents prior to protein
separation by gel electrophoresis. As shown in Fig. 1A (left
panels), the 45-kDa precursor form of CatL[B] and a 43-kDa
protein were secreted and accumulated at all stages of infection
by both mock- and virus-infected cells. The former was detected
as a strong immunoreactive band and the latter as a thin
immunoreactive band. Minute amounts of the 40-kDa fragmentwere noticed in the medium of virus-infected cells at post-
infection (p.i.) day 7 (and at earlier time points if TCF was
concentrated). The 32-kDa fully processed, mature form of CatL
[B] was only detected in the medium of EboVZ- and EboVZe−-
infected cells at 3 days p.i., and its levels increased throughout the
infection period. The relative amounts of the 43- and 32-kDa
bands in Fig. 1A (left panel) correlated with the relative amounts
of protein shown in Fig. S1; in contrast, this was not the case for
the 45- and 40-kDa fragments. These observations indicate that
the pro-enzyme (45-kDa) underwent processing to the 40-kDa
but not to the 32-kDa species during the original purification
steps. This confirms that the enzymatically active, 32-kDa
molecule in the purified material indeed originated from the TCF
from virus-infected cells. At present, it is not clear whether the
40-kDa species is an intermediate in the processing that results in
the mature 32-kDa form.
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proteolytic activity, it has to be converted to the mature 32-kDa
enzyme, a step that usually requires a pH below 5.0 and/or
reducing agents. Although EboV-infected cells can acidify their
extracellular milieu (Fig. 1B, closed circles), this acidification is
not sufficient for procathepsin to undergo autoactivation as
demonstrated by the results shown in Fig. 1A. Nishinaka et al.
(1997) showed that CatL[B] (called Spase in their work) is
predominantly localized in both the nucleus and cytoplasm of
monkey kidney cells as 32-kDa CatL[B] (Fig. 4A in their
publication). This was also observed by us in a Western blot
analysis of cellular extracts. Therefore, the mature form of CatL
[B] in the extracellular environment is likely derived from an
intracellular pool of preactivated enzyme. The mechanism of
32-kDa CatL[B] release is still unclear and beyond the scope of
the present study. However, we suggest the following plausible
mechanisms for 32-kDa CatL[B] extracellular release by EboV-
infected cells: (i) since a number of studies have demonstrated
that endosomal cathepsins can be redistributed towards the cell
membrane and be secreted, and this process is facilitated by the
acidic extracellular pH (pHe) induced under pathologic
conditions (Rozhin et al., 1994; Linebaugh et al., 1999; Webb
et al., 2001; selected references), exocytosis of endosomal
cathepsin is a real possibility. (ii) Alternatively, mature CatL[B]
may be released via the intracellular secretory pathway since
32-kDa CatL[B] exists as a single 32-kDa protein, bearing the
C-terminal sequence (ASAASYPTV) that is identical to the
secretion signal reported for human CatL (known as the major
excreted protein) (Chauhan et al., 1998; Nomura and Katu-
numa, 2005). (iii) Protease leakage associated with necrotic cell
death may also be a possibility.
Knowledge of the extracellular pH is an important parameter
for understanding cathepsins' activities. Cathepsins are known to
cleave peptide bonds by two catalytic mechanisms, each of which
has a different optimal pH (Polgar and Csoma, 1987). At acidic pH
of 4.5–5.5 (like that in lysosomes and other acidic cellular
compartments), it acts as a lysosomal cysteine protease, exhibiting
mainly exopeptidase activity. Above pH 5.5, the enzyme acts
mainly as an endopeptidase. For the later activity, the optimal pH is
close to physiological pH, as expected for an enzyme in the
extracellular environment. Time dependent measurements of the
pHe in EboV-infected cultures are currently unavailable. However,
it has been known for years that in EboV-infected culture medium
the pH indicator phenol red changes color from red to yellow
during the course of infection, indicating that the physiological pHe
drops by at least 0.2 pH units. In the present work, we therefore
carried out pHe measurements with an electrode throughout an
extended period of infection. A detailed description of the
measurement process in a biosafety-level 4 (BSL-4) laboratory
can be found in Materials and methods. Fig. 1B (closed circles)
demonstrates that EboV-infected cells progressively lower the pH
of the culture medium, and this change is most pronounced for
cells infected with the more cytotoxic EboVZe− variant. In our
experiments, the pHe in EboVZ
e− and EboVZ-infected cells began
to drop to below initial levels about 3 and 4 days after infection,
respectively, and reached 6.5 (EboVZe−) and 6.9 (EboVZ) on p.i.
day 7. Interestingly, we noticed that the pHe in close proximity tothe adherent cells was more acidic (by 0.2–0.3 pH units from the
values reported in Fig. 1B) than that measured elsewhere in the
supernatant. This suggests that a different microenvironment exists
at the cell surface, and it is likely that the local pH at the virus-
infected cell surface is even more acidic.
In a system undergoing chronic acidification, it seems
unlikely that a mature cathepsin in the extracellular milieu
remains latent and inactive. We attempted to detect protease
activity in culture medium from infected Vero E6 cells, using a
fluorimetric assay that uses the substrate Z-Arg-Arg-AMC. The
assay was conducted in the BSL-4 laboratory on non-
concentrated samples and in the absence of enzymatic activity
enhancers. As late as day 7 p.i. (even with pH adjustment to
6.0), no significant protease activity was observed in the
harvested medium from infected cultures. One plausible
explanation for this lack of activity may be the presence of
natural inhibitors or inactivation of the enzyme by oxidizing
agents (Linebaugh et al., 1999). In addition, these measure-
ments are complicated by the presence of serum and other
proteinaceous substrates that suppress the fluorescence signal
due to substrate competition with Z-Arg-Arg-AMC. Indeed, the
addition of 2% serum into the enzymatic assay of pure CatL[B]
suppressed the fluorescence signal by ∼50%. Given these
difficulties, the enzymatic activity in TCF is typically assessed
with assays conducted on samples prepared in serum-free media
that are concentrated 100- to 200-fold in the presence of
enzymatic activity enhancers, such as urea and low pH (5.0–
5.5). Other assays commonly used to detect activity in TCF are
zymography and antibody captured protease assays. We did not
explore these alternatives with virus-infected cultures because,
in our opinion, the results of such experiments would not
represent authentic conditions and add no further information
over that derived from our Western blot analysis.
Since we detected CatL[B] on the cell surface of non-
permeabilized intact cells by an immunofluorescence assay
(IFA) (data not shown), we carried out time dependent
measurements of enzymatic activity directly in intact cells, as
described in Materials and methods. In this experiment, the
enzymatic activity assayed is known as pericellular (membrane-
associated and secreted) cathepsin activity (Rozhin et al., 1994).
Hanks' balanced salts solution (HBBS) buffered with HEPES to
pH 7.0 was suitable for use in assaying cathepsin activity
pericellularly in living cells since it prevents activation of
procathepsin by low pH and minimizes relocation of endosomal
proteases during the short incubation period with substrate
(Rozhin et al., 1994). In addition, CatL[B] retains enzymatic
activity at pH 7.0 (Table S1). With this buffer system, the cell
monolayers we began with stay intact throughout the entire
90-min incubation period. Fig. 2 demonstrates that there is little
proteolytic activity prior to day 2 in virus-infected cells, with a
progressive increase in activity starting on days 3 and 4. The
appearance of enzymatic activity was accompanied by sig-
nificant amounts of the 32-kDa protease (Fig. 1A, left panel) and
the metabolic acidification of the cellular supernatant (Fig. 1B,
closed circles). The activity was completely inhibited by E64
(Fig. 2) and significantly reduced by CA074 (Table S2) and no
activity was detectable in mock-infected cells.
Fig. 3. Quantitation of cystatin C in infected TCF. Aliquots (10 μL), in
duplicates, of the same TCF harvested in (A) were diluted 150-fold, and cystatin
C was quantitated using a sandwich ELISA kit from BioVendor, LLC.
Concentration of cystatin C in TCF was directly determined from a standard
curve for human cystatin C. Results are reported as total concentrations of
cystatin C (ng/mL) in TCF.
Fig. 2. Pericellular activity of cathepsin(s) protease in infected cells. After
different time points, infected cells in medium lacking inhibitor were washed
with PBS and preincubated with pH 7.0 assay buffer either with (+I) or without
(− I) CP inhibitor E64. Activity was measured with Z-Arg-Arg-AMC substrate
and reported as relative fluorescence units (R.F.U.) after subtracting the
background. Each time point represents the average of duplicates.
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activity assay is also a substrate for CatB monkey orthologue,
we also investigated whether CatB was released during the
infection process. To that end, supernatants and cellular lysates
were analyzed by Western blot, using the same mAb against
CatB that was used by Nishinaka et al. (1997). Mature CatB was
immunodetected only in TCF from virus-infected cells that
were 10-fold concentrated (data not shown). The data shown in
Fig. 2, therefore, represent the total cathepsin activity from CatL
[B] and CatB. At present, there is no assay to distinguish
quantitatively between monkey CatB and CatL[B] activities
(see Table S1 and discussion above). However, the fact that
CA074 (an non-cell-permeable inhibitor) did not completely
inhibit the pericellular activity (shown in Table S2) suggests that
this activity is not entirely due to CatB and that the residual
activity arises from incomplete inhibition of CatL[B].
What other enzymatic activities may interfere with our
current assay? In preliminary experiments, the assays were
carried out in the presence of inhibitors for metalloprotease
(1 mM EDTA), serine protease (0.1 mM phenylmethylsulpho-
nylfluoride (PMSF) and 0.2mM aprotinin) and CP (50 μME64).
The only inhibitor that resulted in a decrease in the pericellular
activity was E64; all other inhibitors had no effect on the activity.
Therefore, the hydrolysis of the Z-Arg-Arg-AMC substrate is
strictly linked to cathepsin(s). We also considered whether other
cathepsins could interfere with our assay, although the lack of
available biochemical and enzymatic characterization of these
monkey orthologues made our results difficult to interpret. And
the assumption that they will behave like the counterpart human
cathepsin is not guaranteed. We therefore cannot exclude the
possibility that any of these proteases may exhibit similar
substrate specificity and sensitivity towards protease inhibitors
as CatL[B] and CatB. Given all the above, we conclude that
cathepsin(s) activity is present in the acidic extracellularenvironment of EboV-infected cells, with both CatL[B] and
CatB among the proteases redistributed and released as active
enzymes into the extracellular space.
It has been established that in many diseases that are caused
by uncontrolled activity of cathepsin, including cathepsin B and
L, the level of the natural CP inhibitor (CPI) cystatin C is
significantly decreased (Henskens et al., 1996; Grubb, 2000).
Since cystatin C levels will have a direct influence on the
measurable cathepsin activity, the amount of cystatin C in the
TCF was determined. As shown in Fig. 3, cystatin C is detected
in both mock- and virus-infected cells. However, the rate of CPI
release into the culture medium slowed down in virus-infected
samples at 3 days p.i. and at 4 days p.i., the levels of cystatin
were depleted in TCF from EboVZe−-infected samples and
appreciably decreased in TCF from EboVZ-infected samples.
These data indicate that a CPI/CP imbalance exists and that the
infected cells are not be protected from proteolysis by protease
inhibitors that normally counterbalance levels of cysteine
proteases (CatL[B] and CatB).
Intrigued by the observation of increased cathepsin activity
and decreased amounts of CPI in the acidic extracellular milieu
of EboV-infected cells, we speculated that release of mature
cathepsin (including CatL[B] and CatB) by EboV-infected cells
is a host response that contributes to the aggressive nature of
EboV infection. We therefore investigated the effect of the
powerful, non-membrane permeable CP inhibitor E64 on viral
cytopathogenicity of EboVZ and EboVZe– infection of Vero
E6 cells. Fig. 4A gives a general view under light microscope
of such cells. Signs of viral infection become apparent at
differed times after infection by the two viruses. Cells begin to
round up at p.i. days 2 (EboVZe−) and 3 (EboVZ) and to detach
at days 3–4 (EboVZe−) and 4–5 (EboVZ) after infection,
concomitant with the onset of cell death (Fig. 4B), significant
release of cathepsin activity (Fig. 1A [left panel] and Fig. 2),
the acidification of the medium (Fig. 1B [closed circles]) and
depletion of natural CPI (Fig. 3). By day 7 after infection, cell
rounding was complete, and most cells had detached into the
Fig. 4. Post-infection addition of E64 to the cell culture medium inhibited the development of EboV cytopathic effects. (A) Cells viewed under light microscope show
that E64 delays cytopathic effect. Vero E6 cells were infected as described in Fig. 1A. After infection, cells were incubated in maintenance medium either with (+I) or
without (−I) E64. The cells were magnified 20-fold, using a Nikon Eclipse TE2000-U microscope, and examined for cell roundness and detachment. The pictures,
from post-infection days 4 and 7, are representatives of duplicate samples from four independent experiments. (B) E64 significantly improves host survival.
CellQuanti-Blue reagent was added directly to the cultures in 96-well plates, and reduction of resazurin was measured fluorescently after incubating the cells for 90 min
at 37 °C. The results are expressed as a percentage of cell viability compared with that for controls, and the error bars reflect the difference between duplicates. (C) E64
has a weak effect in EboV growth. Viral growth was assessed by determining the levels of viral antigen, using a quantitative sandwich ELISA. The results are presented
as antigen titer and were done two times in duplicates. For (B) and (C), mock, EboVZ and EboVZe− (with [open circles] or without [closed circles] E64) are color coded
green, black and red, respectively.
5Rapid Communicationculture medium, accompanied by significant mortality. If
cathepsin activity was contributing to the viral cytopathic
effect (CPE) and cell death, one would expect to observe a
better preserved cell monolayer and increased cell survival for
cells in the presence of the cathepsin inhibitor E64, and this is
exactly what we saw (cf. Figs. 4A and B). Cell monolayers
stayed intact up to 4 days after infection, and rounding was
only observed at day 7 after infection (later if cells had beenfed). However, no detachment occurred and cell survival was
remarkable. Comparison of viral growth curves (Fig. 4C) in the
absence of inhibitor revealed no significant differences in
replication kinetics for both viruses, while the presence of E64
resulted in a slight growth decrease, alluding to the multiple
roles of cathepsins, such as the release of large quantities of
virions from infected cells and/or cell-to-cell spread of
infection.
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E64 effect is simply related to reduced virus yield (i.e., less
virus produces less cell damage). We consistently noticed that
E64 reduces the viral antigen titer by 0.47–0.74 log10 (Fig. 4C),
and close examination of the data for both EboV strains in Fig. 4
revealed that the amount of virus produced in the presence of
E64 at 7 days p.i. is 0.65–0.79 log10 higher than at 4 d.p.i.
without inhibitor. Furthermore, the cell monolayer is less
damaged at 7 d.p.i. (+I) than at 4 d.p.i. (− I) with no indication
of extracellular matrix degradation at day 7 p.i. in the presence
of inhibitor. The slight changes in cell morphology (like
rounding) are most likely related to the continued production of
large amounts of virus by the infected cells. Other indirect
indications for a small effect of E64 on viral replication are: (i) a
slightly slowed acidification kinetics in virus-infected cells that
were incubated with E64 in the p.i. period (Fig. 1B) and (ii) a
significant release of the 32-kDa protein detected in the culture
medium containing inhibitor (Fig. 1A, right panels). Therefore,
EboV-induced cell damage is accompanied and augmented by
cathepsin-assisted extracellular matrix degradation.
In parallel with our investigation of E64, we also tested
CA074, a non-membrane permeable inhibitor of CatB and CatL
[B] (Table S1). Table S3 shows that the viral antigen titer at day
4 p.i. for EboVZ and EboVZe− was reduced by 0.3 log10 and
0.33 log10 respectively, and the cell monolayer (not shown)
looked very similar to that at day 4 p.i. (+I) (Fig. 4A) for both.
An equivalent experiment at high MOI was also carried out, and
the post-infection period was allowed to proceed in the presence
or absence of E64. Fig. S3 illustrates that mature protease is
present (at day 2 p.i.) concomitant with the initial observation of
extracellular matrix damage (Fig. S4A). A reduction in cystatin
C levels was also noticed, starting at day 2 p.i.: measured
amounts of cystatin C in mock-/EboVZe−-infected cultures at
days 1, 2 and 3 days p.i. are 220/200, 314/234 and 615/273 ng/
mL, respectively. Reduced viral growth by E64 is 0.67 log10
(Fig. S4B), and the amount of virus produced in the presence of
E64 at day 3 p.i. is 0.31 log10 higher than at day 2 p.i. without
inhibitor. The cell monolayer is less damaged at day 3 p.i. (+I)
than at day 2 p.i. (− I). All these observations correlate well with
the results obtained at 0.1 MOI.
At present, it is not clear how E64 interferes with viral yields.
Fig. S2 shows that incubation of cells with E64 before infection
did not affect viral growth, indicating that E64 at low
concentration (50 μM) cannot permeate the cell membranes.
Similar results were obtained with CA074 (data no shown). We
also tested the activity of inhibitors with respect to cytotoxicity
by assessing the ability of the cells to propagate in the presence
of different concentrations of inhibitor and by following
rounding and detachment of cells from the monolayer. We
confirmed that, for the concentrations of all inhibitors used in
our study, no toxic effects are apparent that may affect EboV
replication. There still remains the interesting possibility that
E64 (and CA074) is capable of accessing intracellular
compartments of cells that have been damaged by viral attack
and thereby inhibit CPs. Using the cell-permeable inhibitors
E64d and Z-FY(t-Bu)-DMK (effective inhibitors of CatL[B]
(Table S1) and CatB), viral production was significantlyreduced (by 1.5–1.8 log10) and cell monolayer remained intact.
Therefore, we can conclude that: (i) intracellular cathepsins play
a role in viral replication; (ii) non-cell-permeable inhibitors E64
and CA074 do not significantly inhibit viral replication; and (iii)
extracellular cathepsin activity plays a major role in enhancing
EboV-induced cell damage, and this enzymatic activity occurs
simultaneously with cell detachment and the first signs of
damage to the extracellular matrix. Whether the intracellular
cathepsin activity revealed here is related to the cathepsin-
assisted viral uncoating during viral entry as described by
Chandran et al. (2005) or to the proteolytic processing essential
for virus maturation and release cannot be ascertained at the
present stage. With respect to the later possibility, Pager and
Dutch (2005) recently reported that CatL is intimately involved
with the proteolytic processing of the Hendra virus fusion
protein in Vero E6 cells, a critical step in the generation of a
mature and fusogenic form of the virus.
The extraordinary pathobiology of Ebola virus is a complex
phenomenon involving mechanisms that are not fully under-
stood. To date, there are no sufficient data to explain the severity
at which EboV causes damage and malfunction of its host, and
to the best of our knowledge, the EboV genome does not encode
its own protease. Here we demonstrate that EboV-infected cells
release fully processed and mature host proteases from an
intracellular pool of pre-activated enzyme and that the cell
surface microenvironment is crucial for extracellular protease
activity. CatL[B], one of the active proteases detected in the
extracellular milieu, can catalyze the in vitro degradation of
extracellular matrix components and induces cell rounding and
detachment (Fig. S5). Our most fascinating observations pertain
to the remarkable improvement in CPE and cell survival in the
presence of E64, despite the unmitigated ability of EboZ to
replicate and be released at high viral titer. Therefore, cathepsin
proteases are implicated as contributors to cell destruction, with
this effect being more severe in infections with the highly
cytopathic strain EboVZe−. The degree of metabolic acidifica-
tion and reduced levels of natural protease inhibitors are
intimately involved with this process.
In summary, our experiments provide evidence that
acidification of the extracellular milieu around EboV-infected
cells in conjunction with reduced levels of natural protease
inhibitors leads to uncontrolled proteolysis of matrix by
released endosomal proteases. These results provide a novel
explanation for the severity of Ebola infection and the viral
cytopathic effects in infected culture cells. This viral strategy to
boost infection resulting in uncontrolled cell damage and death
may represent a general strategy also employed by other viruses
that induce cell damage, and more attention should be placed to
investigate the presence of released cellular proteases derived
from virus-infected cells. For instance, Geisbert et al. (2003)
proposed that EboV-induced coagulopathy results primary from
vascular disruption (the hallmark of Ebola virus hemorrhagic
fever) induced by still unknown factors secreted from infected
monocytes/macrophages and dendritic cells. Furthermore, our
study revealed that in cell culture EboV-infected cells acidify
their surroundings to appreciable levels. If similar results are
true in vivo, novel approaches to maintain normal pH levels in
7Rapid Communicationthe organism may be worth exploring. Metabolic acidosis is
known to contribute to multiorgan failure, shock and finally
death, disease pathogenesis clearly associated with Ebola
hemorrhagic fever. A more precise understanding of the cellular
events underlying this pathogenesis undoubtedly will aid in the
development of diagnostic markers, effective prophylaxis and
therapeutic intervention for this devastating disease.
Materials and methods
All work involving infectious materials was conducted under
maximum containment conditions and practices in a BSL-4
laboratory at the Centers for Disease Control and Prevention
(CDC; Atlanta, GA).
Reagents and antibodies
Protease inhibitors, trans-epoxysuccinyl-L-leucylamido (4-
guanidino)-butane (E64), (2S,3S)-trans-epoxysuccinyl-L-leu-
cylamido-3-methylbutane ethyl ester (E64d), [L-3-trans-(pro-
pylcarbamoyl)oxirane-2-carbony]-L-isoleucyl-L-proline
(CA074), Z-Phe-Tyr(t-Bu)-diazomethylketone (Z-FY(t-Bu)-
DMK), aprotinin, ethylenediaminetetracetic acid (EDTA) and
phenylmethylsulfonyl fluoride (PMSF); aminomethylcoumarin
(AMC) synthetic peptide Z-Arg-Arg-AMC; and cysteine were
purchased from Calbiochem (La Jolla, CA). E64d, CA074, Z-
FY(t-Bu)-DMK and the synthetic peptide were prepared as
stock solutions in dimethylsulfoxide (DMSO); PMSF in
methanol; and the stock solutions of other reagents were
prepared in aqueous solution. The following antibodies were
used: anti-Ebola antibodies for EboV antigen detection in the
sandwich ELISA (from the Special Pathogen Branch's
Disease Assessment Team, CDC); anti-CatL (clone 33/2)
and anti-CatB (Ab-1) mAbs (Sigma Chemical Co [St. Louis,
MO] and Calbiochem, respectively); horseradish peroxidase-
conjugated goat anti-mouse and goat anti-rabbit IgG anti-
bodies (KPL; Gaithersburg, MD). All chemicals used were
analytical reagent grade and were obtained from commercial
sources.
Cell line and virus strains
Low-passage stock of the 1976Mayinga strain of Ebola virus
(a Zaire subtype) (EboVZ) and stock of recombinant EboVZ
virus lacking the editing site required for transcription of the
soluble glycoprotein SGP (EboVZe−) were kindly provided by
Anthony Sanchez (CDC). The viruses were propagated in Vero
E6 monkey kidney cells (ATCC No CRL-1586).
Cell culture
Vero E6 monkey kidney cells were propagated in Dulbecco's
modified eagle medium (Invitrogen, Carlsbad, CA) supplemen-
ted to contain high glucose and 10% fetal bovine serum (FBS;
Hyclone; Logan, UT) as well as 2 mM L-glutamine, 100 U/mL
penicillin G sodium, 100 μg/mL streptomycin sulfate and
0.025 μg/mL amphotericin B per milliliter (all from Invitro-gen). Cells were seeded into 12- or 96-well polystyrene
culture plates at 37 °C in a 5% CO2 atmosphere and used for
viral infection or mock experiments once confluent. The
confluent cell monolayer was maintained in the same medium
with FBS decreased to 2%.
Infection of cells
Confluent cell monolayers in 12- or 96-well plates were
infected at MOI of 0.1 (or higher, only as indicated) with a
suspension of virus in growing medium. Adsorption was
allowed to proceed for 1 h at 37 °C in a 5% CO2 atmosphere.
Non-adsorbed virus was removed from cells by washing
monolayers twice with PBS followed by adding fresh main-
tenance medium (with or without CP inhibitor E64 [50 μM] or
CA074 [25 μM] or E64d [50 μM] or Z-FY(t-Bu)-DMK
[2.5 μM]) for the length of the incubation period. For expe-
riments performed with inhibitors, a second dose was re-
supplied to culture medium 4 days after infection. At p.i. days 1,
2, 3, 4 and 7 (unless otherwise indicated), supernatants were
harvested and pH measured, and Western blot analysis and
fluorometric enzymatic assays of CatL[B] were performed, as
was ELISA for cystatin C and viral antigen detection. Cells were
examined under the microscope for CPE and assayed for
pericellular enzymatic activity and cell viability. For some
experiments, the Vero cells were pretreated for 3 h with 50 μM
E64 (or, as indicated, 25 μMCA074) at 37 °C and then infected
at ∼0.1 MOI, and the virus was internalized in the presence of
E64 (or CA074) for 1 h at 37 °C in a 5% CO2 atmosphere. After
infection, steps were performed as described above without E64
(or CA074).
Enzymatic activity and immunodetection of CatL[B] in
culture medium
At the prescribed times after infection, aliquots of culture
supernatants were centrifuged at 14,000×g for 15 min. A
portion (50 μL) of the cleared supernatant was used to
immediately measure proteolytic activity. Each 50 μL aliquot
was mixed with 25 μL of 4× assay buffer (consisting of 4 mM
cysteine and 8 mM EDTA, with or without 200 μM E64, in pH
6.0 MES buffer) and preincubated at room temperature for
10 min. The fluorogenic peptide substrate Z-Arg-Arg-AMC
(25 μL) was then added, and the sample was incubated for 90
min at 37 °C. All reactions were stopped by the addition of
E64 (to a final concentration of 150 μM) and treated with 1%
SDS (see below) before being removed from the BSL-4
laboratory. The free AMC was measured on a Spectra Max
Gemini XS fluorescence plate reader (Molecular Devices,
Sunnyvale, CA) at an excitation wavelength of 360 nm and
emission wavelength of 460 nm. Another portion (180 μL) of
the cleared supernatant was held at −80 °C for later use in
Western blot analysis. Prior to freezing, 20 μL of a 10×
cocktail of protease inhibitors (20 mM EDTA, 1 mM PMSF,
1500 μM E64 and 2 mM aprotinin in 500 mM Tris–HCl
buffer, pH 8.0) was added. The cocktail-containing portion
was then aliquoted (20 μL each) to prevent freeze/thaw cycles.
8 Rapid CommunicationWestern blot analysis was done as described in the
Supplementary materials and methods section, and an anti-
CatL mAb (clone 33/2) (Nishinaka et al., 1997) was used. The
samples were treated with SDS (see below) before removal
from the BSL-4 laboratory. Four independent experiments
were done in duplicate wells. The blots were also probed with
an anti-CatB mAb (Ab-1) (Nishinaka et al., 1997).
pH measurement in culture medium
Due to work requirements in the BSL-4 laboratory and
variations of pH outside the CO2 incubator, a non-glass pH
meter with a fast-response silicon chip pH sensor (IQ125
miniLab; Hach Company, Loveland, CO) was used. For high
accuracy (±0.1 pH) in the measurement, two-point calibration
was performed before each measuring session according to the
manufacturer's instructions. The plates were moved (one at a
time) from the CO2 incubator to the biosafety cabinet, and a
single drop (20 μL) of the TCF was immediately pipetted into
the tip of the probe, ensuring that both the reference junction
and the pH sensor were covered. Readings were achieved
within 1–2 s. Measurements were performed in duplicate
wells.
Pericellular activity assay
At a given time after infection, mock- and virus-infected
cells in 96-well cell culture plates were washed twice with
PBS (pH 7.4) and then 100 μL of HBSS (Invitrogen)
supplemented with 2.5 mM cysteine and adjusted to pH 7.0
with 15 mM HEPES was added to each well. After a 15 min
incubation at room temperature in the presence or absence of
50 μM E64 (or, as indicated, 25 μM CA074), the cells were
challenged by the addition of 25 μL of a 75 μM stock solution
of Z-Arg-Arg-AMC substrate in 1% DMSO (15 μM substrate,
0.2% DMSO final concentration), and the reaction was
incubated for 90 min in a 37 °C CO2 incubator. The reaction
was stopped by the addition of E64 (to a final concentration of
150 μM) and treated with 1% SDS (see below) before removal
from the BSL-4 laboratory. Fluorescence was measured as
described above. The experiment was performed in duplicate
wells.
Cystatin C detection by ELISA
Aliquots (10 μL), in duplicates, of the same TCF harvested
for Western blot analysis were diluted 150-fold, and the cystatin
C levels were determined using a sandwich ELISA kit from
BioVendor, LLC (Cadler, NC) in accordance with the
manufacturer's instructions.
Evaluation of viral cytopathic effect by microscopy
Tissue cultures were examined daily for CPE under a light
microscope, using a Nikon Eclipse TE2000-U system with a
Retiga EXi camera attached. Four separate experiments were
performed in duplicates.Assay for measuring cell viability
The ability of viable cells to reduce resazurin to resorufin was
measured using the fluorescence-based CellQuanti-Blue assay kit
from Bioassay Systems (Hayward, CA). This reagent was added
directly to cultures (containing both adherent cells and suspension
cells that were detached due to CPE) as described in the company
protocol, and the fluorescence of the medium was assayed after
incubating the compounds with cells for 90 min. After this
incubation period elapsed, the supernatants were harvested and
centrifuged at 14,000×g for 15 min followed by SDS treatment
(see below) before removal from the BSL-4 laboratory. Fluores-
cence was then measured at excitation and emission wavelengths
of 530 and 590 nm, respectively. The fluorescence was expressed
as a percentage of cell viability compared with that for control
cells, after subtraction of background fluorescence. Measurements
were performed in duplicate wells.
ELISA protocol for EboV antigen detection
Viral growth was assessed by measuring EboV antigen levels
by ELISA since this assay is not affected by the presence of
protease inhibitors in the samples. Supernatants were harvested and
gamma-irradiated as described below. EboV antigens were
quantified using a sandwich ELISA exactly as previously
described (Ksiazek et al., 1992). Antigen levels were calculated
by subtracting the optical density (OD)405 in control wells from the
OD of the same sample in test wells. The highest dilution of sample
that resulted in a corrected OD ≥0.1 was designated the viral
antigen titer of the sample. Supernatants assayed were harvested
from two separate experiments performed in duplicate wells.
SDS and gamma radiation inactivation
We found in preliminary experiments that processing of CatL
[B] can be triggered by SDS and gamma radiation inactivation—
the only methods currently approved at CDC for treatment of
infectious samples before their removal from the BSL-4 laboratory.
To prevent the introduction of this artifactual processing, we
optimized our procedures by adjusting first the pH of the cleared
samples to 8.0 with 10× Tris–HCl buffer (500 mM, pH 8.0) in the
presence of a cocktail of protease inhibitors (20 mM EDTA, 1 mM
PMSF, 1500 μM E64 and 2 mM aprotinin in 500 mM Tris–HCl
buffer, pH 8.0). The samples were then treated with SDS at a final
concentration of 1% SDS and transferred to an Eppendorf tube.
The tube was tightly closed and immersed in a Lysol® bath before
being removed from the BSL-4 laboratory.
Gamma radiation inactivation was suitable for samples used for
viral antigen detection (Elliott et al., 1982). The cocktail of
protease inhibitors was also added to a 1× final concentration, and
Eppendorf tubes containing samples were sealed on double heat-
sealed plastic bags and then immersed in a Lysol® bath before
being removed from the BSL-4 laboratory. The samples were
irradiated to a dose of 5×106 rad of gamma radiation while kept
frozen in dry ice. The gamma radiation source was a gamma cell
containing 60Co (model Gammacell 220 Excel; MDS Nordion,
Ottawa, Canada). All samples were held at −70 °C until assayed.
9Rapid CommunicationTreatment of Vero E6 cells with CatL[B]
Confluent monolayers of cells in a 96-well plate were washed
with PBS and incubated at 37 °C with 0.1 μg and 0.01 μg of
purified CatL[B] (Fig. S1) in 50 μL HBSS buffer containing
1 mM cysteine (with or without 50 μM E64 or 2.5 μM Z-FY
(t-Bu)-DMK) and with the pH adjusted to 7.0 with HEPES
buffer. Cells were viewed under light microscope and pictures
were taken.
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